trending Market Intelligence /marketintelligence/en/news-insights/trending/E2sk9kbrMZHxt_H2-TQjIw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Regen BioPharma seeking patent protection for T-cell tumor treatment

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Regen BioPharma seeking patent protection for T-cell tumor treatment

Regen BioPharma Inc. is seeking U.S. patent protection for a method to use T cells when treating solid tumors.

The company filed a utility patent application with the U.S. Patents and Trademark Office for killing solid tumors using NR2F6-silenced CAR T cells.

"By activating the adaptive arm of the immune system, in the form of NR2F6-silenced T cells, we anticipate achieving synergistic effects in killing of solid tumors, something which has not been observed in previous CAR-T approaches," Regen BioPharma President and Chief Scientific Officer Harry Lander said.